ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.999,47
0,00%
S&P 500
5.867,08
-0,09%
Dow Jones
42.342,24
0,04%
Euro vs US Dollar
1,03735
0,09%
Bitcoin
97.783,62
0,33%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Avalo Therapeutics Inc (AVTX) Börsenkurse

Avalo Therapeutics Inc

Avalo Therapeutics Inc (AVTX)

Avantium NV
9,08
-0,20
(-2,16%)
Geschlossen 20 Dezember 10:00PM
Verzögert um 15 Minuten
9,11
0,03
(0,33%)
Nach Börsenschluss: 1:59AM
Verzögert um 15 Minuten

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
9,08
Gebot
4,00
Fragen
12,00
Volumen
65.099
9,11 Tagesbereich 9,99
3,9501 52-Wochen-Bereich 34,46
Marktkapitalisierung
94,377M
Handelsende
9,28
Handelsbeginn
9,99
Letzte Trade
1
@
9.44
Letzter Handelszeitpunkt
Finanzvolumen
US$ 614.140
VWAP
9,4339
Durchschnittliches Volumen (3 Mio.)
61.197
Ausgegebene Aktien
10.393.954
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-0,97
Gewinn pro Aktie (EPS)
-3,03
Erlöse
1,92M
Nettogewinn
-31,54M

Über Avalo Therapeutics Inc

Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing... Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
www.avalotx.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Avalo Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AVTX. The last closing price for Avalo Therapeutics was US$9,28. Over the last year, Avalo Therapeutics shares have traded in a share price range of US$ 3,9501 to US$ 34,46.

Avalo Therapeutics currently has 10.393.954 shares in issue. The market capitalisation of Avalo Therapeutics is US$96,46 million. Avalo Therapeutics has a price to earnings ratio (PE ratio) of -0.97.

AVTX Neueste Nachrichten

Weitere Nachrichten

Form 8-K - Current report

05 Dezember 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 November 2024
Edgar (US Regulatory)

Form 8-K - Current report

12 November 2024
Edgar (US Regulatory)

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to $185 millionCash runway expected into at...

12 November 2024
GlobeNewswire Inc.

Avalo Therapeutics to Present at Upcoming Investor Conferences

WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation...

11 November 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

07 November 2024
Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans

07 November 2024
Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans

07 November 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 November 2024
Edgar (US Regulatory)

Form 8-K - Current report

07 November 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.15-1.625135427959.239.928.771253289.29449917CS
4-1.84-16.849816849810.92128.77972929.68012509CS
12-0.11-1.196953210019.19168.49266119711.08397095CS
26-2.03-18.271827182711.11166.843788910.87370156CS
52-2.56-21.993127147811.6434.463.950176303113.54781353CS
156-403.72-97.8003875969412.81711.23.9501791410036.01093931CS
260-679.72-98.6817653891688.81711.23.9501720250439.30624748CS

AVTX - Frequently Asked Questions (FAQ)

What is the current Avalo Therapeutics share price?
The current share price of Avalo Therapeutics is US$ 9,08
How many Avalo Therapeutics shares are in issue?
Avalo Therapeutics has 10.393.954 shares in issue
What is the market cap of Avalo Therapeutics?
The market capitalisation of Avalo Therapeutics is USD 96,46M
What is the 1 year trading range for Avalo Therapeutics share price?
Avalo Therapeutics has traded in the range of US$ 3,9501 to US$ 34,46 during the past year
What is the PE ratio of Avalo Therapeutics?
The price to earnings ratio of Avalo Therapeutics is -0,97
What is the cash to sales ratio of Avalo Therapeutics?
The cash to sales ratio of Avalo Therapeutics is 15,83
What is the reporting currency for Avalo Therapeutics?
Avalo Therapeutics reports financial results in USD
What is the latest annual turnover for Avalo Therapeutics?
The latest annual turnover of Avalo Therapeutics is USD 1,92M
What is the latest annual profit for Avalo Therapeutics?
The latest annual profit of Avalo Therapeutics is USD -31,54M
What is the registered address of Avalo Therapeutics?
The registered address for Avalo Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Avalo Therapeutics website address?
The website address for Avalo Therapeutics is www.avalotx.com
Which industry sector does Avalo Therapeutics operate in?
Avalo Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
PRFXPainReform Ltd
US$ 11,08
(410,60%)
95,4M
NVNINVNI Group Ltd
US$ 2,66
(315,63%)
20,64M
BPTHBio Path Holdings Inc
US$ 1,50
(124,22%)
113,42M
ZCARZoomcar Holdings Inc
US$ 2,5999
(96,96%)
18,03M
APCXAppTech Payments Corporation
US$ 0,6203
(62,81%)
196,08M
LITMSnow Lake Resources Ltd
US$ 0,3025
(-63,09%)
72,24M
BSFCBlue Star Foods Corporation
US$ 0,1478
(-48,14%)
7,45M
QUBTQuantum Computing Inc
US$ 15,1396
(-41,05%)
122,47M
QMCOQuantum Corporation
US$ 36,02
(-39,99%)
7,07M
AEMDAethlon Medical Inc
US$ 0,4232
(-35,94%)
9,52M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,561
(53,78%)
725,18M
NVDANVIDIA Corporation
US$ 130,68
(1,37%)
209,74M
APCXAppTech Payments Corporation
US$ 0,6203
(62,81%)
196,08M
RGTIRigetti Computing Inc
US$ 7,465
(-30,17%)
176,12M
SOUNSoundHound AI Inc
US$ 18,855
(-9,55%)
139,39M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
AVTX
Avalo Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten